


**Amendments to the Claims**

1. (Previously Presented) A compound of formula I:



or a pharmaceutically acceptable acid addition salt thereof, where;

Q is oxygen or sulfur;

X is  $-C(R^{4c})=$  or  $-N=$ ;

$R^1$  is mono-, di-, or tri-substituted phenyl wherein the substitutions are independently selected from halo,  $C_1-C_2$  alkoxy, trifluoromethyl, trifluoromethoxy, and trifluoroethoxy;

$R^2$  is hydrogen or methyl;

$R^3$  is hydrogen;

$R^{4a}$  and  $R^{4b}$  are hydrogen

When X is  $-C(R^{4c})=$ ,  $R^{4c}$  is hydrogen

$R^5$  is hydrogen; and


$R^6$  is hydrogen.

2. – 8 (Cancelled)

9. (Currently Amended) A pharmaceutical composition comprising a compound according to Claim 1 and a pharmaceutical carrier, diluent, or excipient.

10. – 13 (Cancelled)

14. (Currently Amended) A method for the treatment or prevention of migraine in a mammal comprising administering to a mammal in need of such treatment or prevention an effective amount of a compound of formula I:



or a pharmaceutically acceptable acid addition salt thereof, where;

Q is oxygen or sulfur;

X is  $-C(R^{4c})=$  or  $-N=$ ;

R<sup>1</sup> mono- di-, or tri-substituted phenyl wherein the substitutions are independently selected from halo, C<sub>1</sub>-C<sub>2</sub> alkoxy, trifluoromethyl, trifluoromethoxy, and trifluoroethoxy;

R<sup>2</sup> is hydrogen or methyl;

R<sup>3</sup> is hydrogen;

R<sup>4a</sup> and R<sup>4b</sup> are hydrogen;

When X is  $-C(R^{4c})=$ , R<sup>4c</sup> is hydrogen;


R<sup>5</sup> is hydrogen; and

R<sup>6</sup> is hydrogen

15. (Original) The method according to Claim 14 wherein the mammal is a human.

16.- 28 (Cancelled)

29. (Previously Presented) A compound of formula I:



or a pharmaceutically acceptable acid addition salt thereof, where;

Q is oxygen or sulfur;

X is  $-C(H)=$  or  $-N=$ ;

R<sup>1</sup> is a substituted or unsubstituted heterocycle wherein the heterocycle is selected from the group consisting of pyridinyl and thiophenyl;

R<sup>2</sup> is hydrogen or methyl;

R<sup>3</sup> is hydrogen;


R<sup>4a</sup> and R<sup>4b</sup> are hydrogen

R<sup>5</sup> is hydrogen; and

R<sup>6</sup> is hydrogen.

30. (Currently Amended) A pharmaceutical composition comprising a compound according to Claim 29 and a pharmaceutical carrier, diluents, or excipient.

31. (Currently Amended) A method for the treatment or prevention of migraine in a mammal comprising administering to a mammal in need of such treatment or prevention an effective amount of a compound of formula I;



or a pharmaceutically acceptable acid addition salt thereof, where;

Q is oxygen or sulfur;

X is -C(H)= or -N=;

R<sup>1</sup> is a substituted or unsubstituted heterocycle wherein the heterocycle is selected from the group consisting of pyridinyl and thiophenyl;

R<sup>2</sup> is hydrogen or methyl;

R<sup>3</sup> is hydrogen;

R<sup>4a</sup> and R<sup>4b</sup> are hydrogen

R<sup>5</sup> is hydrogen; and

R<sup>6</sup> is hydrogen.

32. (Previously Presented) The method according to Claim 31 wherein the mammal is human.